NCT05583175View on ClinicalTrials.gov

Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
Leukemia, Myeloid, AcuteMDSHematopoietic Stem Cell TransplantationMyeloid Malignancy
Interventions
DRUG

Venetoclax plus RIC

Eligible patients will receive Venetoclax plus RIC regimen allogeneic transplantation. The treatment regimen is: Venetoclax 100mg/d - 10d, 200mg/d - 9d (first use and NR or untreated MDS), 400mg/d, - 8d\~ - 2d (7d); Fludarabine: 30mg/m2/d, - 6d\~-2d (5d), Cytarabine: 1g/m2/d, - 6d\~-2d (5d) Busulfan: 3.2mg/m2/d, - 6d\~-5d (2d), TBI: 3 Gray, - 1d.

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Xianmin Song, MD

OTHER